The Src homology (SH)2–containing inositol 5-phosphatase (SHIP) negatively regulates a variety of immune responses through inhibitory immune receptors. In SHIP−/− animals, we found that the number of early lymphoid progenitors in the bone marrow was significantly reduced and accompanied by expansion of myeloid cells. We exploited an in vitro system using hematopoietic progenitors that reproduced the in vivo phenotype of SHIP−/− mice. Lineage-negative marrow (Lin−) cells isolated from wild-type mice failed to differentiate into B cells when cocultured with those of SHIP−/− mice. Furthermore, culture supernatants of SHIP−/− Lin− cells suppressed the B lineage expansion of wild-type lineage-negative cells, suggesting the presence of a suppressive cytokine. SHIP−/− Lin− cells contained more IL-6 transcripts than wild-type Lin− cells, and neutralizing anti–IL-6 antibody rescued the B lineage expansion suppressed by the supernatants of SHIP−/− Lin− cells. Finally, we found that addition of recombinant IL-6 to cultures of wild-type Lin− bone marrow cells reproduced the phenotype of SHIP−/− bone marrow cultures: suppression of B cell development and expansion of myeloid cells. The results identify IL-6 as an important regulatory cytokine that can suppress B lineage differentiation and drive excessive myeloid development in bone marrow.
Skip Nav Destination
Article navigation
19 January 2004
Article|
January 12 2004
Src Homology 2–containing 5-Inositol Phosphatase (SHIP) Suppresses an Early Stage of Lymphoid Cell Development through Elevated Interleukin-6 Production by Myeloid Cells in Bone Marrow
Koji Nakamura,
Koji Nakamura
1Immunobiology and Cancer Program, Oklahoma Medical Research Foundation, Oklahoma City, OK 73104
Search for other works by this author on:
Taku Kouro,
Taku Kouro
1Immunobiology and Cancer Program, Oklahoma Medical Research Foundation, Oklahoma City, OK 73104
Search for other works by this author on:
Paul W. Kincade,
Paul W. Kincade
1Immunobiology and Cancer Program, Oklahoma Medical Research Foundation, Oklahoma City, OK 73104
2Department of Microbiology and Immunology, University of Oklahoma, Oklahoma City, OK 73104
Search for other works by this author on:
Alexander Malykhin,
Alexander Malykhin
1Immunobiology and Cancer Program, Oklahoma Medical Research Foundation, Oklahoma City, OK 73104
Search for other works by this author on:
Kazuhiko Maeda,
Kazuhiko Maeda
1Immunobiology and Cancer Program, Oklahoma Medical Research Foundation, Oklahoma City, OK 73104
Search for other works by this author on:
K. Mark Coggeshall
K. Mark Coggeshall
1Immunobiology and Cancer Program, Oklahoma Medical Research Foundation, Oklahoma City, OK 73104
2Department of Microbiology and Immunology, University of Oklahoma, Oklahoma City, OK 73104
3Department of Cell Biology, University of Oklahoma, Oklahoma City, OK 73104
Search for other works by this author on:
Koji Nakamura
1Immunobiology and Cancer Program, Oklahoma Medical Research Foundation, Oklahoma City, OK 73104
Taku Kouro
1Immunobiology and Cancer Program, Oklahoma Medical Research Foundation, Oklahoma City, OK 73104
Paul W. Kincade
1Immunobiology and Cancer Program, Oklahoma Medical Research Foundation, Oklahoma City, OK 73104
2Department of Microbiology and Immunology, University of Oklahoma, Oklahoma City, OK 73104
Alexander Malykhin
1Immunobiology and Cancer Program, Oklahoma Medical Research Foundation, Oklahoma City, OK 73104
Kazuhiko Maeda
1Immunobiology and Cancer Program, Oklahoma Medical Research Foundation, Oklahoma City, OK 73104
K. Mark Coggeshall
1Immunobiology and Cancer Program, Oklahoma Medical Research Foundation, Oklahoma City, OK 73104
2Department of Microbiology and Immunology, University of Oklahoma, Oklahoma City, OK 73104
3Department of Cell Biology, University of Oklahoma, Oklahoma City, OK 73104
Address correspondence to K. Mark Coggeshall, Oklahoma Medical Research Foundation, 825 NE 13th St., Oklahoma City, OK 73104. Phone: (405) 271-7209; Fax: (405) 271-8569; email: [email protected]
Abbreviations used in this paper: FcγRII, Fcγ receptor II; NOD, nonobese diabetic; PI-3K, phosphatidylinositol 3-kinase; PIP3, phosphatidylinositol 3,4,5-trisphosphate; SH, src homology; SHIP, SH2-containing 5-inositol phosphatase.
Received:
July 17 2003
Accepted:
December 02 2003
Online ISSN: 1540-9538
Print ISSN: 0022-1007
The Rockefeller University Press
2004
J Exp Med (2004) 199 (2): 243–254.
Article history
Received:
July 17 2003
Accepted:
December 02 2003
Citation
Koji Nakamura, Taku Kouro, Paul W. Kincade, Alexander Malykhin, Kazuhiko Maeda, K. Mark Coggeshall; Src Homology 2–containing 5-Inositol Phosphatase (SHIP) Suppresses an Early Stage of Lymphoid Cell Development through Elevated Interleukin-6 Production by Myeloid Cells in Bone Marrow . J Exp Med 19 January 2004; 199 (2): 243–254. doi: https://doi.org/10.1084/jem.20031193
Download citation file:
Sign in
Don't already have an account? Register
Client Account
You could not be signed in. Please check your email address / username and password and try again.
Could not validate captcha. Please try again.
Sign in via your Institution
Sign in via your InstitutionSuggested Content
Email alerts
Advertisement